Unlike traditional chemotherapy dosed by body surface area, TKIs for GIST are dosed based on individual patient tolerance. Therapeutic drug monitoring of plasma levels has not proven effective. The standard approach is to start all patients at a recommended dose and then adjust based on side effects to find the highest tolerable dose that maintains efficacy.

Experienced oncologists are improving the tolerability of the mTOR inhibitor everolimus by starting at 5mg or 7.5mg daily, rather than the 10mg label dose, for many patients. This practical, off-label dose adjustment has made the drug a more manageable and viable option for combination therapy in the modern era.

For patients with significant comorbidities like cardiovascular disease, proactively starting lenvatinib at a reduced dose (e.g., 14mg instead of 20mg) is a practical strategy to mitigate anticipated severe toxicities from the outset.

Current solid TKI pills, especially capsules, make fine-tuned dose adjustments difficult. A liquid formulation would offer crucial flexibility, allowing for precise dosing (e.g., 350mg instead of 400mg) to manage the dose-response relationship. It would also be ideal for patients with feeding tubes or GI issues who cannot tolerate or swallow solid pills, preventing treatment delays.

Data on Enfortumab Vedotin suggests that for modern therapies, maintaining patients on treatment longer via a lower, more tolerable starting dose is more important than administering the maximum labeled dose upfront, a concept inherited from the cytotoxic chemotherapy era.

The Phase 2 TRAIT study suggests starting adjuvant abemaciclib at a lower dose and escalating over several weeks significantly reduces early discontinuations due to side effects like diarrhea. This strategy helps more patients get through the initial high-toxicity period and remain on the effective dose for the full two-year course.

Tyrosine kinase inhibitors (TKIs) have dramatically increased median overall survival for GIST patients from nine months to over seven years. Some patients have now been on therapy for over 20 years. This longevity transforms GIST into a chronic condition, making long-term side effect management and quality of life critical for maintaining treatment adherence and efficacy.

Clinicians recommend starting lenvatinib at the full 20mg dose rather than escalating from a lower dose. This ensures therapeutic levels are reached. They then dose-reduce aggressively as needed. Starting low risks falsely concluding the drug is ineffective if the patient tolerates a suboptimal dose without response.

Clinicians recommend starting abemaciclib at 100mg BID, rather than the standard 150mg, to mitigate initial GI toxicity. This dose-escalation approach, supported by the TRADE study, improves long-term adherence and allows more patients to reach the target dose without discontinuing.